在HER2-阴性晚期乳腺癌患者的后伊利布林治疗中确定与免疫相关的预测因素 - 一项多中心回顾性研究
Yuri Takamatsu1, Yoshiya Horimoto1,2, Yasuo Miyoshi3
1Department of Breast Oncology, Faculty of Medicine, Juntendo University, Tokyo, Japan.
International journal of clinical oncology
|January 31, 2026
概括
埃里布林 (ERI) 改善了HER2阴性晚期乳腺癌的存活率. 在ERI治疗期间和之后保持高绝对淋巴细胞计数 (ALC) 对于更好的结果至关重要.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 埃里布林 (ERI) 单疗法证明了在HER2-阴性晚期乳腺癌 (ABC) 中改善整体存活率 (OS).
- 之前的分析确定了基线绝对淋巴细胞计数 (ALC) 作为ERI疗效的预测标记.
- 影响后ERI结果的因素,特别是免疫状况,仍未得到充分研究.
研究的目的:
- 调查与改善后ERI总生存率 (OS2) 相关的因素.
- 探索ERI治疗期间绝对淋巴细胞计数 (ALC) 动态的影响.
- 为了确定治疗ERI的HER2-阴性晚期乳腺癌患者的预后标志物.
主要方法:
- 对370名HER2-阴性ABC患者的回顾性分析,这些患者接受了ERI治疗.
- 提取临床数据,包括在ERI启动和终止时的ALC.
- 使用日志等级测试和Cox危险模型进行统计分析,以确定OS1和OS2.
主要成果:
- 在ERI启动时更高的ALC (≥1000/μL) 和ER阳性状态与改善的OS1.1相关.
- 改善OS2的独立预测因素包括在ERI终止时ALC≥1000/μL,治疗终止时间≥120天和一线ERI使用.
- 在ERI治疗期间,ALC保持不变,但在其他治疗方案中显著下降 (P < 0.001).
结论:
- 在 ERI 完成时的 ALC ≥1000/μL 与后 ERI OS (OS2) 的改善有关.
- 在ERI完成时的免疫状态,除了基线因素外,还具有预后价值.
- 在ERI治疗期间维持ALC可能是HER2-负ABC的长期存活的关键因素.
相关概念视频
02:49Cancer Therapies
10.2K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.2K
01:29Factors Affecting Protein-Drug Binding: Patient-Related Factors
323
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
323
02:57Targeted Cancer Therapies
8.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.9K
01:23Negative Regulator Molecules
38.5K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.5K
02:27Predicting Molecular Geometry
45.8K
VSEPR Theory for Determination of Electron Pair Geometries
45.8K
01:38What is the Immune System?
127.9K
Overview
127.9K